Ctrl K
Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.59 | — | — | — | — | — | — | — | 1.01 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 2359.02 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | — | 2.44 | 1.37 | — | 1.61 | — | 2.56 | 2.00 | 5.17 | — | 483.92 | 6.00 | 2.67 | — | — | — | 43.76 | 5.41 | 9.24 | 5.46 | 5.16 |
| — | — | -46.7% | — | -68.8% | — | -99.5% | -66.6% | +93.5% | — | — | — | -93.9% | — | — | — | +748.7% | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | 0.43 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | 0.43 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 100.0% | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -123506.2% | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -55498.2% | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -521.6% | -21.3% | -27.7% | -269.2% | -263.0% | -222.6% | -56.6% | -2.0% | 371.3% | — | -189.8% | -55.4% | -25.7% | — | — | — | -123.5% | -41.2% | -35.4% | -27.4% | -290.0% |
| — | +90.4% | +51.0% | -13328.9% | -170.8% | — | +70.2% | +96.4% | +1543.1% | — | — | — | +79.2% | — | — | — | +57.4% | — | — | — | — | |
| ROA | -282.8% | -18.9% | -21.5% | -69.7% | -74.8% | -87.4% | -45.1% | -1.1% | 71.6% | -105.8% | -42.3% | -18.9% | -18.0% | -72.1% | -71.9% | -86.5% | -58.0% | -17.6% | -10.3% | -8.9% | -6.5% |
| — | +78.4% | +52.3% | -6250.1% | -204.5% | +17.4% | -6.6% | +94.2% | +498.2% | -46.8% | +41.1% | +78.1% | +69.0% | -309.4% | -594.5% | -873.1% | -788.5% | -525.8% | +90.7% | +86.5% | +95.3% | |
| ROIC | — | — | — | — | — | — | -260.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1.08 | 0.69 | 0.50 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 0.88 | 7.85 | 9.92 | 0.88 | 1.76 | 0.97 | 3.36 | 8.52 | 9.30 | 0.44 | 1.34 | 1.46 | 1.81 | 0.17 | 0.51 | 1.08 | 1.73 | 5.42 | 10.37 | 19.07 | 13.29 |
| — | +711.5% | +194.8% | -89.7% | -81.1% | +117.8% | +150.9% | +485.2% | +413.1% | +162.5% | +164.8% | +35.3% | +4.8% | -96.9% | -95.1% | -94.4% | -87.0% | -18.1% | +149.7% | +3589.7% | +6481.6% | |
| Quick Ratio | 0.88 | 7.85 | 9.92 | 0.88 | 1.76 | 0.97 | 3.36 | 8.52 | 9.30 | 0.44 | 1.34 | 1.46 | 1.81 | 0.17 | 0.51 | 1.08 | 1.73 | 5.42 | 10.37 | 19.07 | 13.29 |
| — | +711.5% | +194.8% | -89.7% | -81.1% | +117.8% | +150.9% | +485.2% | +413.1% | +162.5% | +164.8% | +35.3% | +4.8% | -96.9% | -95.1% | -94.4% | -87.0% | -18.1% | +149.7% | +3589.7% | +6481.6% | |
| Interest Coverage | — | — | — | — | — | — | — | -0.08 | — | — | -46.35 | -45.62 | -30.30 | -46.01 | — | — | — | -19.44 | -13.18 | -14.55 | -7.59 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PMN stock.
ProMIS Neurosciences, Inc.'s current P/E is -0.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking ProMIS Neurosciences, Inc.'s business trajectory between earnings reports.